Graypoint LLC Sells 104 Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Graypoint LLC reduced its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 3.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 2,902 shares of the pharmaceutical company’s stock after selling 104 shares during the quarter. Graypoint LLC’s holdings in Vertex Pharmaceuticals were worth $1,169,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently modified their holdings of VRTX. MGO One Seven LLC boosted its stake in shares of Vertex Pharmaceuticals by 98.5% in the 2nd quarter. MGO One Seven LLC now owns 3,221 shares of the pharmaceutical company’s stock valued at $1,510,000 after purchasing an additional 1,598 shares during the last quarter. LPL Financial LLC boosted its stake in shares of Vertex Pharmaceuticals by 14.4% in the 2nd quarter. LPL Financial LLC now owns 209,839 shares of the pharmaceutical company’s stock valued at $98,356,000 after purchasing an additional 26,468 shares during the last quarter. Main Street Financial Solutions LLC boosted its stake in shares of Vertex Pharmaceuticals by 16.4% in the 2nd quarter. Main Street Financial Solutions LLC now owns 2,699 shares of the pharmaceutical company’s stock valued at $1,265,000 after purchasing an additional 381 shares during the last quarter. Oppenheimer & Co. Inc. boosted its stake in shares of Vertex Pharmaceuticals by 8.7% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 13,729 shares of the pharmaceutical company’s stock valued at $6,435,000 after purchasing an additional 1,099 shares during the last quarter. Finally, DekaBank Deutsche Girozentrale boosted its stake in shares of Vertex Pharmaceuticals by 2.1% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 501,509 shares of the pharmaceutical company’s stock valued at $237,126,000 after purchasing an additional 10,380 shares during the last quarter. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX opened at $409.56 on Friday. Vertex Pharmaceuticals Incorporated has a 52-week low of $377.85 and a 52-week high of $519.88. The company has a 50-day simple moving average of $448.88 and a 200 day simple moving average of $468.03. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.20 and a current ratio of 2.47. The company has a market capitalization of $105.47 billion, a PE ratio of -205.81 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The business had revenue of $2.77 billion during the quarter, compared to the consensus estimate of $2.69 billion. During the same quarter last year, the company posted $3.67 earnings per share. The firm’s quarterly revenue was up 11.6% compared to the same quarter last year. On average, research analysts predict that Vertex Pharmaceuticals Incorporated will post -1.83 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on the stock. Oppenheimer lowered shares of Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Bank of America cut their target price on shares of Vertex Pharmaceuticals from $545.00 to $522.00 and set a “buy” rating on the stock in a research note on Thursday, December 19th. BMO Capital Markets cut their target price on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a research note on Friday, December 20th. Canaccord Genuity Group increased their target price on shares of Vertex Pharmaceuticals from $361.00 to $408.00 and gave the stock a “sell” rating in a research note on Wednesday, November 6th. Finally, Stifel Nicolaus increased their target price on shares of Vertex Pharmaceuticals from $490.00 to $494.00 and gave the stock a “hold” rating in a research note on Monday, December 16th. Three investment analysts have rated the stock with a sell rating, ten have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $490.38.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.